That would probably be this one:
/clinicaltrials.gov/ct2/show/NCT02202447It's a PSMA antibody attached to tubulysin. Tubulysin is cytotoxic, so the hope is that the PSMA antibody will attach to the PSMA on the surface of prostate cancer cells, and the tubulysin will kill the cell it attaches to. Several kinds of chemotherapy, like docetaxel, also are effective because they affect the tubulin in cancer cells. The hope is that this agent will me much more specific to prostate cancer cells, and so will be less toxic to healthy cells.
It looks like an interesting trial. Please let us know how it turns out.
- Allen